US009511075B2

(12) **United States Patent**
Simard

(10) **Patent No.: US 9,511,075 B2**
(45) **Date of Patent: Dec. 6, 2016**

(54) **TARGETING $NC_{CA\text{-}ATP}$ CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE**

(75) Inventor: **J. Marc Simard**, Baltimore, MD (US)

(73) Assignees: **The University of Maryland, Baltimore**, Baltimore, MD (US); **The United States of America as Represented by the Dept. of Veterans Affairs**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1811 days.

(21) Appl. No.: **12/522,444**

(22) PCT Filed: **Jan. 11, 2008**

(86) PCT No.: **PCT/US2008/050922**

§ 371 (c)(1),
(2), (4) Date: **Jan. 27, 2010**

(87) PCT Pub. No.: **WO2008/089103**

PCT Pub. Date: **Jul. 24, 2008**

(65) **Prior Publication Data**

US 2010/0143347 A1 Jun. 10, 2010

Related U.S. Application Data

(60) Provisional application No. 60/880,119, filed on Jan. 12, 2007, provisional application No. 60/923,378, filed on Apr. 13, 2007, provisional application No. 60/952,396, filed on Jul. 27, 2007, provisional application No. 61/012,613, filed on Dec. 10, 2007.

(51) **Int. Cl.**

A61K 31/64	(2006.01)
A61K 31/57	(2006.01)
G01N 33/68	(2006.01)
A61K 31/121	(2006.01)
A61K 39/395	(2006.01)
A61K 31/427	(2006.01)
A61K 31/565	(2006.01)
A61K 38/00	(2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/57*** (2013.01); ***G01N 33/6872*** (2013.01); *A61K 31/427* (2013.01); *A61K 31/565* (2013.01); *A61K 38/00* (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,047,429	A	9/1991	Nve et al.	514/592
5,166,162	A	11/1992	Masereel et al.	514/339
5,215,985	A	6/1993	Murphy et al.	514/217.11
5,236,932	A	8/1993	Greenfield et al.	514/305
5,281,599	A	1/1994	Murphy et al.	514/305
5,451,580	A	9/1995	Murphy et al.	514/217.11
5,545,656	A	8/1996	Loose et al.	514/414
5,677,344	A	10/1997	Greenfield et al.	514/592
5,811,393	A	9/1998	Klassbrun et al.	514/7.6
5,849,796	A	12/1998	Gericke et al.	514/618
5,916,871	A	6/1999	Johnson	514/16.5
5,929,082	A	7/1999	Chambers et al.	514/272
5,962,645	A	10/1999	Keay et al.	530/350
6,043,224	A	3/2000	Lee et al.	514/26
6,056,977	A	5/2000	Bhagwat et al.	424/488
6,100,047	A	8/2000	Wilkison et al.	435/7.2
6,156,522	A	12/2000	Keay et al.	435/7.1
6,180,671	B1	1/2001	Freedman et al.	
6,184,248	B1	2/2001	Lee et al.	514/474
6,187,756	B1	2/2001	Lee et al.	514/26
6,232,289	B1	5/2001	Keav et al.	514/7.6
6,242,200	B1	6/2001	Wilkison et al.	435/7.21
6,365,577	B1	4/2002	Iversen	514/44
6,372,743	B1	4/2002	Darrow et al.	514/246
6,376,197	B1	4/2002	Keay et al.	435/7.1
6,469,055	B2	10/2002	Lee et al.	514/474
6,492,130	B1	12/2002	Wilkison et al.	435/14
6,492,339	B1	12/2002	Sleevi et al.	
6,511,989	B2	1/2003	Heitsch et al.	514/311
6,569,633	B1	5/2003	Wilkison et al.	435/7.21
6,569,845	B1	5/2003	Futamura et al.	514/178
6,596,751	B2	7/2003	Fuiita et al.	514/394
6,610,746	B2	8/2003	Fryburg et al.	514/592
6,613,785	B2	9/2003	Bril et al.	514/369

(Continued)

FOREIGN PATENT DOCUMENTS

AU	2003222020	A1	10/2003
EP	0338415	A3	3/1991
EP	0467709	A3	7/1992
EP	1 782 815		5/2007
ES	P200401628		6/2004

(Continued)

OTHER PUBLICATIONS

Simard et al, Nature Medicine, 2006, vol. 12, No. 4, pp. 433-439.*

(Continued)

Primary Examiner — Elizabeth C Kemmerer

Assistant Examiner — Fozia Hamud

(74) *Attorney, Agent, or Firm* — Norton Rose Fulbright US LLP

(57) **ABSTRACT**

The present invention concerns protection of an organ or tissue following an ischemic episode In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1 Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.

25 Claims, 17 Drawing Sheets